SAJE Pharma
SAJE Pharma
  • Home
  • About Us
  • What's New
  • Science
  • Development
  • Safety
  • Intellectual Property
  • Pipeline & Status
  • Collaborators & Advisors
  • Publications
  • More
    • Home
    • About Us
    • What's New
    • Science
    • Development
    • Safety
    • Intellectual Property
    • Pipeline & Status
    • Collaborators & Advisors
    • Publications
  • Home
  • About Us
  • What's New
  • Science
  • Development
  • Safety
  • Intellectual Property
  • Pipeline & Status
  • Collaborators & Advisors
  • Publications

Pipeline and Status

  The chart below illustrates the status of SAJE’s pipeline programs for the drugs and disease models that have been completed to date. SPL-850 and SPL-891.1, both third generation compounds,  have been and are being studied in other animal models of disease. The drug candidates below are being tested in various models of disease using many routes of administration. Safety studies have begun for SPL-850 and SPL-891.1.  Because SPL-850 is more active against GSNOR in vitro and in vivo, it is our lead compound and has the most safety data, all of which show safety at high doses.

image553

Also of interest as strong GSNORis and IL-6 in vivo inhibitors: SPL-847, -894, and -895

Copyright © 2020 SAJE Pharma - All Rights Reserved.

  • Contact Us

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept